SAPIRSTEIN JAMES 4

What Happened
James Sapirstein, CEO of Cocrystal Pharma (COCP), received a grant of 235,000 non‑qualified stock options reported on 2026-06-03. The Form 4 lists the transaction as a derivative award with a reported price of $0.00 (no cash paid at grant). The options were granted under the Issuer’s 2025 Equity Incentive Plan and are subject to the company’s standard Stock Option Agreement.

Key Details

• Transaction date / filing date: 2026-06-03 (Form 4 filed covering the same date).
• Transaction type: Award/grant of 235,000 non‑qualified stock options (derivative). Reported price: $0.00 on the Form 4.
• Vesting: Options vest in four equal annual installments; first vesting on June 3, 2027, subject to continued employment. Potential accelerated vesting may occur on a Change in Control or termination for Cause.
• Approval / exemption: Grant was approved by the Board and exempt from Section 16(b) under Rule 16b-3.
• Shares owned after transaction: Not specified in the provided filing summary.
• Filing timeliness: Reported and filed for the same date (no late filing noted in the provided data).

Context
This was an equity compensation grant (options), not an open‑market purchase or sale — there was no immediate cash transaction or sale of shares. The economic benefit to the insider depends on future stock price movement and exercising the options per the option agreement and vesting schedule. Such grants are commonly used for executive compensation and retention; they do not, by themselves, indicate a near‑term buy or sell by the insider.